FIB-4, APRI, and AST/ALT Ratio Compared to FibroScan for the Assessment of Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease: A Cross-Sectional Study
Abstract
Background: Non-alcoholic fatty liver disease (NAFLD) is now the most prevalent chronic liver disorder globally. Liver fibrosis stage is the primary determinant of prognosis in NAFLD patients. FibroScan (transient elastography) is a validated non-invasive method for fibrosis assessment, but its availability remains limited in resource-constrained settings. Simple serum-based indices offer a potentially cost-effective alternative. Objectives: To evaluate and compare the diagnostic performance of FIB-4 score, APRI score, and AST/ALT ratio against FibroScan for the assessment of hepatic fibrosis in NAFLD patients. Methods: This hospital-based cross-sectional observational study enrolled 150 consecutive NAFLD patients at a tertiary care centre in Jaipur, India over 18 months (March 2024 – August 2025). All participants underwent FibroScan assessment and calculation of FIB-4, APRI, and AST/ALT ratio from standard biochemical parameters. Fibrosis was staged F0–F4 by transient elastography. Statistical analysis was performed using SPSS 29.0; a p-value <0.05 was considered significant. Results: The mean age was 51.41 ± 10.46 years; 62.67% were male. FibroScan-determined fibrosis distribution: F0 (40%), F4 (18%), F0–F1 (17.33%), F2–F3 (16.67%), F3–F4 (8%). All three serum indices — FIB-4, APRI, and AST/ALT ratio — showed statistically significant progressive increases with advancing fibrosis stage (all p < 0.001). In advanced fibrosis (F3–F4 and F4), 100% of patients exceeded the established high-risk thresholds for each index (FIB-4 ≥ 3.4; APRI > 1.5; AST/ALT ≥ 0.8). Mean FIB-4 scores rose from 1.16 ± 0.50 in F0 to 7.92 ± 1.03 in F4; APRI from 0.47 ± 0.16 to 2.62 ± 0.24; and AST/ALT ratio from 0.61 ± 0.15 to 1.50 ± 0.19. Conclusions: FIB-4, APRI, and AST/ALT ratio are reliable, low-cost, and widely accessible non-invasive markers that correlate strongly with FibroScan-determined fibrosis severity in NAFLD patients. FIB-4 demonstrated the greatest discriminative power for advanced fibrosis. These indices are recommended as initial fibrosis triage tools, with FibroScan reserved for patients in the indeterminate risk range.